Nonsteroidal antiinflammatory drug use among patients with GI bleeding

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1159-1164

  Dominick, Kelli L ^a,b,c   Bosworth, Hayden B ^a,b,c   Jeffreys, Amy S ^a   Grambow, Steven C ^a,c   Oddone, Eugene Z ^a,c,d   Horner, Ronnie D ^c,e  

^a DURHAM VA MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Div of General Internal Medicine   (Netherlands)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anti ulcer agents; Nonsteroidal antiinflammatory drugs; Pharmacoepidemiology

Indexed keywords

CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SALSALATE;

ADULT; AGED; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; STOMACH PROTECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COHORT STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RETROSPECTIVE STUDIES; VETERANS;

EID: 3042544225     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E052     Document Type: Article

References (27)

1. National Institute for Health Care Management. Prescription drug expenditures in 2001. Washington, DC: National Institute for Health Care Management, May 6, 2002.
2. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Sloane survey. JAMA 2002;287:337-44.
3. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:1905-15.
4. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
5. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
6. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
7. Lanza FL, Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment of and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998;93:2037-46.
8. Isenberg JI, Soll AH. Epidemiology, clinical manifestations, and diagnosis of peptic ulcer. In: Bennett JC, Plum F. eds. Cecil textbook of medicine. 20th ed. Philadelphia: Saunders, 1996:664-6.
9. Public health and aging: projected prevalence of self-reported arthritis or chronic joint symptoms among persons aged >65 years - United States, 2005-2030. MMWR Morb Mortal Wkly Rep 2003;52:489-91.
10. Day JC. Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. Current population reports. Washington, DC: US Department of Commerce, 1996:25-1130.
11. Helmick CG, Lawrence RC, Pollard RA, Lloyd E, Heyse SP. Arthritis and other rheumatic conditions: who is affected now, who will be affected later? Arthritis Care Res 1995;8:203-11.
12. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
14. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
15. Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990's: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002;97:2540-9.
16. Prescription drug expenditures in 2001. Washington, DC: National Institute for Health Care Management, May 6, 2002.
17. Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol 2002;53:183-8.
18. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Underutilization of gastroprotective measures in patient receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-200.
19. Dominick KL, Bosworth HB, Jeffreys AS, Grambow SC, Oddone EZ, Horner RD. Racial/ethnic variations in nonsteroidal anti-inflammatory drug (NSAID) use among patients with osteoarthritis (DOI 10.1002/ pds.904). Pharmacoepidemiol Drug Saf. www3.interscience.wiley.com/ cgi-bin/jissue/85510548 (accessed 2004 May 27).
20. Dominick KL, Ahern FM, Gold CH, Heller DA. Gender differences in NSAID use among older adults with osteoarthritis. Ann Pharmacother 2003;37:1566-71. DOI 10.1345/aph.1C418
21. Rahme E, Marentette MA, Kong SX, Lelorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.
22. Criteria for the non-formulary use of cyclooxygenase 2 (COX-2) inhibitors in high-risk veteran patients. Washington, DC: Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Veterans Health Administration, Department of Veterans Affairs, November 2001.
23. Lapane KL, Spooner JJ, Mucha L, Straus WL. Effect of nonsteroidal antiinflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 2001;49:577-84.
24. Ofman JJ, Etchason J, Alexander W, Stevens BR, Herrin J, Cangialose C, et al. The quality of care for Medicare patients with peptic ulcer disease. Am J Gastroenterol 2000;95:106-13.
25. US Census Bureau. Guide to the 2002 economic census. http://landview. census.gov/epcd/ec02/g02geo2.htm (accessed 2002 Nov 6).
26. Singh G, Ramey DR, Triadafilopoulos G, Brown BW, Balise RR. GI Score: a simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA (abstract). Arthritis Rheum 1998;41(suppl):S75.
27. Dominick KL, Dudley TK, Grambow SC, Oddone EZ, Bosworth HB. Racial differences in health care utilization among patients with osteoarthritis. J Rheumatol 2003;30:2203-6.